Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 6142-05-8 | MDL No. : | MFCD00270826 |
Formula : | C3H5ClN2S | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | WDJXDOCQCALXMV-UHFFFAOYSA-N |
M.W : | 136.60 g/mol | Pubchem ID : | 80239 |
Synonyms : |
|
Num. heavy atoms : | 7 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 33.48 |
TPSA : | 67.15 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.3 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.18 |
Log Po/w (WLOGP) : | 1.54 |
Log Po/w (MLOGP) : | -0.2 |
Log Po/w (SILICOS-IT) : | 1.67 |
Consensus Log Po/w : | 0.84 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.96 |
Solubility : | 1.5 mg/ml ; 0.011 mol/l |
Class : | Very soluble |
Log S (Ali) : | -2.19 |
Solubility : | 0.89 mg/ml ; 0.00652 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -0.86 |
Solubility : | 19.0 mg/ml ; 0.139 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.02 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
82% | With sodium formate; acetic anhydride; In water; benzene; | EXAMPLE 5 27.5 grams (0.2 mole) of <strong>[6142-05-8]2-aminothiazole hydrochloride</strong> and 13.6 grams (0.2 mole) of sodium formate were suspended in 100 ml of benzene. There were added dropwise at 40 to 45 C. 41 grams (0.4 mole) of acetic anhydride. The mixture was held at 40 to 45 C. for 2 hours, then cooled to 20 C., washed twice, each time with 50 ml of water and subsequently evaporated to dryness under reduced pressure. There were recovered 21 grams of 2-formylaminothiazole, corresponding to a yield of 82%. The substance had a melting point of 142 to 143 C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine; In methanol; at 110℃; for 48h; | Example 58 8-indan-5-yl-5-oxo-2-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid thiazol-2-ylamide (Cpd 131) A solution of 8-indan-5-yl-5-oxo-2-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester (10 mg) and <strong>[6142-05-8]thiazol-2-ylamine hydrochloride</strong> (20 mg) in 1:1 TEA and MeOH (2 mL) was heated in a sealed tube at 110 C. for 2 days. After cooling, water was added and the solution was directly purified (HPLC, C-18 YMC ODS-A 5mu 30*100 mm, 120 A column at 32 mL/min, 5-100% H2O/MeCN (0.1% TFA v/v) gradient over 10 min.) to provide the title compound (2.5 mg). 1H NMR (TFA salt) (400 MHz, CDCl3) delta (ppm): 9.46 (s, 1H), 8.92 (s, 1H), 7.44-7.35 (m, 3H), 7.30-7.23 (m, 4H), 7.13-7.06 (m, 2H), 3.83 (m, 5H), 3.22-3.13 (m, 2H), 3.01-3.07 (m, 4H), 2.78-2.53 (m, 6H), 2.16-2.20 (m, 4H); Mass Spectrum (LCMS, APCI pos.) Calcd. For: C32H31N7O2S: 577.23; Found: 578.2 (M+H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With nitrogen; | Example 13 Preparation of Aminothiazole hydrochloric acid (22) Hydrochloric acid is bubbled through a solution of Boc protected amine (4, 1.4 g, 1.1 mmol) in DCM (20 mL) for thirty min. The reaction mixture is then tightly capped and stirred for thirty minutes after which the reaction mixture is sparged with nitrogen. The mixture loses its gel like appearance. DCM (5 mL) is added to the solution, and HCl gas is bubbled through it for an additional 20 min, followed by nitrogen for 30 min. Crude product (1.32 g) is obtained after concentration as a bright orange solid, and taken on to the next step with no further purification. LCMS: Rt=1.5 min, [M+H]+ 1138. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In pyridine; tert-butyl alcohol; | Step 1 To a solution of chlorosulfonylisocyanate (1.35 g, 9.6 mmol) in DCM (50 mL) at 0 C., is added t-BuOH (918 uL, 9.6 mmol) and stirred for 30 min while maintaining temperature at 0 C. To a solution of amine 22 (820 mg, 0.72 mmol) in pyridine (12 mL) is added 0.2 M solution of sulfonyl chloride (1.44 mmol, 0.72 mL). The reaction is stirred for 5 min at 0 C. The solvents were evaporated in vacuo and the solid is purified by basic alumina flash chromatography (gradient elution: 0-10% MeOH/DCM to provide 220 mg of the boc-sulfonylurea. MS (M+H)+1317. |
[ 72792-54-2 ]
Thiazole-2,4-diamine hydrochloride
Similarity: 0.83
[ 30216-52-5 ]
2-Hydrazinylthiazole hydrochloride
Similarity: 0.83
[ 90586-84-8 ]
N-Ethylthiazol-2-amine hydrochloride
Similarity: 0.77
[ 72792-54-2 ]
Thiazole-2,4-diamine hydrochloride
Similarity: 0.83
[ 30216-52-5 ]
2-Hydrazinylthiazole hydrochloride
Similarity: 0.83
[ 90586-84-8 ]
N-Ethylthiazol-2-amine hydrochloride
Similarity: 0.77